Post Transplant High-Dose Cy as GvHD Prophylaxis in 1 HLA Mismatched Unrelated HSCT for Myeloid Malignancies (GITMO-PHYLOS)
Post Transplant High-Dose Cyclophosphamide as GvHD Prophylaxis in Patients Receiving 1-Antigen/Allele HLA Mismatched (7/8 Matched) Unrelated Hemopoietic Stem Cell Transplantation for Myeloid Malignancies
Sponsor: Gruppo Italiano Trapianto di Midollo Osseo
A PHASE2 clinical study on Myeloid Malignancies, this trial is completed. The trial is conducted by Gruppo Italiano Trapianto di Midollo Osseo and has accumulated 12 data snapshots since 2020. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Apr 2023 — Jul 2024 [monthly]
Completed PHASE2
Status: Recruiting → Completed
-
Dec 2022 — Apr 2023 [monthly]
Recruiting PHASE2
▶ Show 7 earlier versions
-
Sep 2021 — Dec 2022 [monthly]
Recruiting PHASE2
-
Apr 2021 — Sep 2021 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jan 2021 — Apr 2021 [monthly]
Not Yet Recruiting PHASE2
-
Dec 2019 — Jan 2021 [monthly]
Not Yet Recruiting PHASE2
-
Sep 2018 — Dec 2019 [monthly]
Not Yet Recruiting PHASE2
-
Jun 2018 — Sep 2018 [monthly]
Not Yet Recruiting PHASE2
-
Sep 2017 — Jun 2018 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Gruppo Italiano Trapianto di Midollo Osseo
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Alessandria, Italy , Ancona, Italy , Avellino, Italy , Bari, Italy , Bergamo, Italy , Bologna, Italy , Bolzano, Italy , Brescia, Italy , Cagliari, Italy , Cuneo, Italy and 19 more locations